The United States Food and Drug Administration (FDA) has issued a formal warning letter to Unomedical, a prominent subsidiary of the global medical products company Convatec, following a series of inspections that revealed significant deficiencies in the manufacturer’s quality control, complaint handling, and adverse event reporting. Unomedical serves as a critical link in the global diabetes care supply chain, manufacturing insulin infusion sets for several of the world’s leading insulin pump technology firms, including Medtronic, Tandem Diabetes Care, and Beta Bionics. The regulatory action highlights a pattern of systemic failures at the company’s Reynosa, Mexico, facility, where inspectors identified risks that could lead to life-threatening complications for patients living with insulin-dependent diabetes.
The warning letter, which was made public following a remote regulatory assessment conducted in the summer of 2024, outlines a troubling history of uninvestigated product failures. At the heart of the FDA’s concerns are leaking infusion sets—the plastic tubing and cannula systems that deliver a continuous flow of insulin from a pump into a patient’s body. When these sets leak or fail to maintain physical integrity, patients receive less insulin than programmed, a condition known as under-delivery. For individuals with Type 1 diabetes, even a brief interruption in insulin delivery can lead to hyperglycemia (high blood sugar) and, more severely, diabetic ketoacidosis (DKA). DKA is a medical emergency characterized by the buildup of acids called ketones in the blood; if left untreated, it can result in coma or death.
A Massive Backlog of Uninvestigated Safety Complaints
Perhaps the most alarming revelation in the FDA’s warning letter is the scale of unaddressed safety reports. According to the document, Unomedical closed more than 41,000 complaints received between June 2023 and June 2025 without conducting any formal investigation. The company justified these closures by citing missing lot numbers for the devices in question. However, the FDA countered that the lack of a lot number does not absolve a manufacturer of its responsibility to investigate potential safety trends, especially when the complaints involve allegations of leaks, adhesive failures, infections, and even patient death.
The failure to investigate these 41,000 files suggests a significant gap in the company’s post-market surveillance system. In the medical device industry, post-market surveillance is the primary mechanism through which manufacturers identify emerging defects and take corrective action before more patients are harmed. By summarily closing tens of thousands of reports, Unomedical effectively blinded itself—and regulators—to the true scope of its product performance issues.
Furthermore, the FDA noted that between January 2023 and June 2025, Unomedical received more than 5,000 specific complaints related to leaking infusion sets. Many of these reports were accompanied by clinical evidence of patient harm, including documented cases of hyperglycemia and DKA. Despite this high volume of specific feedback, the agency found that Unomedical’s internal processes were insufficient to address the root causes of the leaks.
Deficiencies in Manufacturing Validation and Corrective Actions
The FDA’s warning letter also took aim at Unomedical’s technical manufacturing standards, specifically regarding "process validation." In medical device manufacturing, validation is the objective evidence that a process consistently produces a result meeting its predetermined specifications. Inspectors found that the process Unomedical used to test its infusion sets for leaks had not been properly validated. This means the company could not scientifically prove that its testing methods were sensitive enough to catch defective units before they were shipped to distributors and patients.
The agency also criticized the company’s "Corrective and Preventive Action" (CAPA) protocols. A CAPA is a fundamental requirement of the FDA’s Quality System Regulation, requiring companies to investigate the cause of nonconformities and verify that their fixes are effective. The warning letter highlighted a specific instance involving the Varisoft infusion set, which Unomedical manufactures for Tandem Diabetes Care.
Between December 2022 and October 2023, Unomedical received 210 complaints regarding Varisoft tubing detaching from its connector. This defect led to at least 80 reports of hyperglycemia. Although Unomedical eventually identified a defective manufacturing machine as the culprit and took corrective action, the FDA found that the company’s verification of that fix was incomplete. Specifically, Unomedical excluded several known complaints of hyperglycemia from its final verification check, leading the agency to conclude that the company had not sufficiently proven the problem was resolved. Furthermore, the FDA pointed out that Unomedical waited more than 11 months after becoming aware of the defect before initiating a recall in October 2023, a delay that potentially exposed thousands of patients to unnecessary risk.
Failure to Meet Adverse Event Reporting Deadlines
Under the Medical Device Reporting (MDR) regulations, manufacturers are legally obligated to report incidents to the FDA within 30 days if they learn of a device-related death or serious injury. The warning letter asserts that Unomedical repeatedly failed to meet these deadlines.
In one cited example, Unomedical learned in September 2024 of a complaint involving four AutoSoft XC infusion sets (another product manufactured for Tandem) that leaked during use, resulting in serious injury via elevated blood glucose readings. Despite having the information, the company failed to submit the required MDRs within the 30-day window. This lack of transparency prevents the FDA’s "Manufacturer and User Facility Device Experience" (MAUDE) database from providing an accurate, real-time picture of device safety to the public and healthcare providers.
Response from Convatec and Unomedical
In the wake of the FDA’s public disclosure of the warning letter, Convatec issued a statement on February 3, 2025, seeking to reassure investors and the diabetes community. The parent company emphasized that the FDA’s concerns are focused on administrative reporting procedures and internal quality protocols rather than the inherent design of the products. Crucially, Convatec noted that the warning letter does not currently place any restrictions on the production, marketing, or distribution of Unomedical’s infusion sets.
"We are committed to the highest standards of quality and safety," the company stated, noting that they are working transparently with the FDA to resolve the issues. As part of its remediation plan, Unomedical has committed to a multi-stage corrective strategy. This includes:
- A retrospective review of all complaints involving serious injury or death, scheduled for completion by January 2026.
- An overhaul of complaint-handling procedures to ensure that missing lot numbers no longer prevent investigations.
- Comprehensive staff training on regulatory reporting requirements, to be completed by May 2025.
- Opening new corrective actions to address leaks in "extended wear" infusion sets, which have been the subject of more than 3,000 recent complaints.
Impact on Partners and the Diabetes Technology Market
The regulatory scrutiny on Unomedical has ripple effects across the entire insulin pump industry. Companies like Tandem Diabetes Care and Medtronic rely on Unomedical as a primary original equipment manufacturer (OEM) for their infusion sets. Because these sets are proprietary and specifically designed to interface with certain pump models, switching manufacturers is a complex, multi-year process involving new regulatory filings.
Tandem Diabetes Care, in particular, has a significant portion of its product line tied to Unomedical’s manufacturing, including the AutoSoft, Varisoft, and TruSteel brands. While Tandem has not reported a supply shortage, the FDA’s findings regarding the 11-month delay in the Varisoft recall suggest that pump manufacturers may need to exert more rigorous oversight over their third-party suppliers.
For patients, the news is a reminder of the "last-mile" vulnerability in diabetes technology. While insulin pumps have become highly advanced—featuring automated insulin delivery (AID) algorithms and integration with continuous glucose monitors (CGM)—the system still relies on a simple plastic tube and adhesive patch. If the physical delivery mechanism fails, the most advanced software in the world cannot prevent the onset of hyperglycemia.
Broader Industry Implications and Regulatory Analysis
The FDA’s use of a "Remote Regulatory Assessment" (RRA) to identify these issues reflects an evolving post-pandemic regulatory landscape. During the COVID-19 pandemic, the FDA began using remote tools to inspect facilities when travel was restricted. The fact that an RRA of the Reynosa facility led to a full-scale warning letter indicates that the agency is successfully integrating digital oversight into its enforcement toolkit.
This case also serves as a stark warning to the medical device industry regarding "lot number" policies. The FDA’s rejection of Unomedical’s excuse for closing 41,000 complaints sets a clear precedent: manufacturers are expected to use all available data—including patient narratives and clinical outcomes—to investigate failures, even when specific manufacturing identifiers are missing.
As Unomedical works toward the deadlines set for 2025 and 2026, the medical community will be watching closely to see if the company can restore its quality systems to compliance. For now, the FDA continues to monitor the situation, and healthcare providers are encouraged to report any suspected infusion set malfunctions through the MedWatch program. The situation underscores the critical balance between rapid innovation in diabetes tech and the fundamental necessity of rigorous, transparent manufacturing standards to ensure patient safety.